Omada Health
+59%
est. 2Y upside i
Virtual care platform for chronic condition prevention and management
Rank
#745
Sector
Digital Health / Virtual Care
Est. Liquidity
~0Y
Data Quality
Data: HighOmada Health offers a compelling equity opportunity for a job candidate, with a public stock providing liquidity and a 2-year expected upside of ~59% net of dilution.
Last updated: July 19, 2026
Revenue reaches ~$496M with exit multiple at 7x, driven by GLP-1 partnership expansion and sustained profitability. Net of 15% dilution, return is 85%.
Revenue grows to ~$496M with exit multiple converging to 5x, in line with public comps. Net of 15% dilution, return is 60.8%.
Multiple compresses to 3x due to competitive pressure from Teladoc/Hinge Health and slower growth. After 15% dilution, return is -9.5%.
Preference Stack Risk
severeFunding Intensity
159%Total preferred liquidation preference of $450M over $1.41B valuation (31.9% overhang); likely converted upon IPO but still a risk if not.
Dilution Risk
moderateExpected 15% dilution over 2 years from employee equity grants and potential secondary offerings.
Secondary Liquidity
activeOmada trades on NASDAQ under OMDA, providing active secondary market liquidity for RSUs upon vesting.
Other — 20 roles
- Accounting Manager, Corporate Accounting · Remote, USA
- Director of Engineering, Member Experience – Core User Experience (B2C) · Remote, USA
- Director, Product Management · Remote, USA
- +17 more →
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Omada Health's data — designed to show you've done your homework.
- 1
“How will Omada differentiate from Teladoc and Hinge Health in the GLP-1 space?”
- 2
“What are the unit economics of a per-member-per-month contract vs. a value-based contract?”
- 3
“What is the expected dilution from employee stock grants over the next 2 years?”
Community
Valuation Sentiment
Our model estimates +59% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.